ArticleAntimicrobial agents and chemotherapy2018
Reversal of Azole Resistance in Candida albicans by Sulfa Antibacterial Drugs.
Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 57 citations in OpenAlex.
- Article
- Lansoprazole interferes with fungal respiration and acts synergistically with amphotericin B against multidrug-resistantEmerging microbes & infections · 2024Article
- Overcoming amphotericin B resistance inAntimicrobial agents and chemotherapy · 2024Article
- Elucidation of the mechanisms of fluconazole resistance and repurposing treatment options against urinary Candida spp. isolated from hospitalized patients in Alexandria, Egypt.BMC microbiology · 2024Article
- Novel aza-bicyclic 2-isoxazoline acylhydrazone hybrids and their synergistic potential with fluconazole against a drug-resistant Candida albicans strain.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- Novel combinatorial approach: Harnessing HIV protease inhibitors to enhance amphotericin B's antifungal efficacy in cryptococcosis.PloS one · 2024Article
- Synergistic potential of lopinavir and azole combinational therapy against clinically important Aspergillus species.PloS one · 2024Article
- Lopinavir and ritonavir act synergistically with azoles against Candida auris in vitro and in a mouse model of disseminated candidiasis.International journal of antimicrobial agents · 2023Article
- Azole potentiation in Candida species.PLoS pathogens · 2023Article
- Atazanavir Resensitizes Candida auris to Azoles.Antimicrobial agents and chemotherapy · 2023Article
- Small molecules for combating multidrug-resistant superbugActa pharmaceutica Sinica. B · 2022Review
- Augmenting Azoles with Drug Synergy to Expand the Antifungal Toolbox.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Article
- Current and promising pharmacotherapeutic options for candidiasis.Expert opinion on pharmacotherapy · 2021Article
- Review
- The effect of intra-articular injection of antibacterial drugs in the clinical treatment of prosthetic joint infection in patients undergoing artificial hip replacement.American journal of translational research · 2021Article
- Potent Synergistic Interactions between Lopinavir and Azole Antifungal Drugs against Emerging Multidrug-Resistant Candida auris.Antimicrobial agents and chemotherapy · 2020Article
- Article
- Antifungal Drug Repurposing.Antibiotics (Basel, Switzerland) · 2020Article
- Genome-Scale Metabolic Model of the Human PathogenJournal of fungi (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Invasive candidiasis presents an emerging global public health challenge due to the emergence of resistance to the frontline treatment options, such as fluconazole. Hence, the identification of other compounds capable of pairing with fluconazole and averting azole resistance would potentially prolong the clinical utility of this important group. In an effort to repurpose drugs in the field of antifungal drug discovery, we explored sulfa antibacterial drugs for the purpose of reversing azole resistance in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.